Astria Therapeutics (NASDAQ:ATXS - Get Free Report) issued its quarterly earnings data on Tuesday. The biotechnology company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.01, Zacks reports.
Astria Therapeutics Stock Performance
Shares of ATXS traded up $0.01 during mid-day trading on Tuesday, hitting $5.83. The company's stock had a trading volume of 20,583 shares, compared to its average volume of 258,663. The firm has a market capitalization of $329.01 million, a PE ratio of -2.79 and a beta of 0.69. Astria Therapeutics has a one year low of $5.75 and a one year high of $16.90. The stock's 50-day moving average is $7.32 and its two-hundred day moving average is $9.65.
Analyst Ratings Changes
A number of research firms have recently weighed in on ATXS. Citizens Jmp upgraded shares of Astria Therapeutics to a "strong-buy" rating in a report on Friday, January 31st. HC Wainwright reissued a "buy" rating and set a $16.00 price objective on shares of Astria Therapeutics in a report on Thursday, February 27th. JMP Securities initiated coverage on Astria Therapeutics in a report on Friday, January 31st. They issued an "outperform" rating and a $26.00 target price for the company. Finally, Oppenheimer increased their price target on Astria Therapeutics from $26.00 to $28.00 and gave the company an "outperform" rating in a report on Thursday, November 14th. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $25.67.
Get Our Latest Stock Report on Astria Therapeutics
About Astria Therapeutics
(
Get Free Report)
Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Astria Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astria Therapeutics wasn't on the list.
While Astria Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
